{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "31185048", "DateCompleted": {"Year": "2020", "Month": "02", "Day": "10"}, "DateRevised": {"Year": "2020", "Month": "12", "Day": "14"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "06", "Day": "11"}], "Language": ["eng"], "ELocationID": ["e0218125", "10.1371/journal.pone.0218125"], "Journal": {"ISSN": "1932-6203", "JournalIssue": {"Volume": "14", "Issue": "6", "PubDate": {"Year": "2019"}}, "Title": "PloS one", "ISOAbbreviation": "PLoS One"}, "ArticleTitle": "A multi-targeting natural compound with growth inhibitory and anti-angiogenic properties re-sensitizes chemotherapy resistant cancer.", "Pagination": {"StartPage": "e0218125", "MedlinePgn": "e0218125"}, "Abstract": {"AbstractText": ["Targeted therapies have become the focus of much of the cancer therapy research conducted in the United States. While these therapies have made vast improvements in the treatment of cancer, their results have been somewhat disappointing due to acquired resistances, high cost, and limited populations of susceptible patients. As a result, targeted therapeutics are often combined with other targeted therapeutics or chemotherapies. Compounds which target more than one cancer related pathway are rare, but have the potential to synergize multiple components of therapeutic cocktails. Natural products, as opposed to targeted therapies, typically interact with multiple cellular targets simultaneously, making them a potential source of synergistic cancer treatments. In this study, a rare natural product, deacetylnemorone, was shown to inhibit cell growth in a broad spectrum of cancer cell lines, selectively induce cell death in melanoma cells, and inhibit angiogenesis and invasion. Combined, these results demonstrate that deacetylnemorone affects multiple cancer-related targets associated with tumor growth, drug resistance, and metastasis. Thus, the multi-targeting natural product, deacetylnemorone, has the potential to enhance the efficacy of current cancer treatments as well as reduce commonly acquired treatment resistance."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemical Engineering, University of South Carolina, Columbia, South Carolina, United States of America."}], "LastName": "Taylor", "ForeName": "Wesley F", "Initials": "WF"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemical Engineering, University of South Carolina, Columbia, South Carolina, United States of America."}], "LastName": "Moghadam", "ForeName": "Sara E", "Initials": "SE"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Phytochemistry, Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, G. C., Evin, Tehran, Iran."}], "LastName": "Moridi Farimani", "ForeName": "Mahdi", "Initials": "M"}, {"Identifier": ["0000-0003-2167-8032"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Phytochemistry, Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, G. C., Evin, Tehran, Iran."}], "LastName": "N Ebrahimi", "ForeName": "Samad", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Phytochemistry, Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, G. C., Evin, Tehran, Iran."}], "LastName": "Tabefam", "ForeName": "Marzieh", "Initials": "M"}, {"Identifier": ["0000-0003-0989-834X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemical Engineering, University of South Carolina, Columbia, South Carolina, United States of America."}, {"Identifier": [], "Affiliation": "Biomedical Engineering Program, University of South Carolina, Columbia, South Carolina, United States of America."}], "LastName": "Jabbarzadeh", "ForeName": "Ehsan", "Initials": "E"}], "GrantList": [{"GrantID": "P20 GM103641", "Acronym": "GM", "Agency": "NIGMS NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article", "Research Support, N.I.H., Extramural"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "PLoS One", "NlmUniqueID": "101285081", "ISSNLinking": "1932-6203"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Angiogenesis Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents, Phytogenic"}], "MeshHeadingList": [{"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Angiogenesis Inhibitors"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Antineoplastic Agents, Phytogenic"}, {"QualifierName": ["drug effects"], "DescriptorName": "Drug Resistance, Neoplasm"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": [], "DescriptorName": "HCT116 Cells"}, {"QualifierName": [], "DescriptorName": "Human Umbilical Vein Endothelial Cells"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Neoplasms"}], "CoiStatement": "The authors have declared that no competing interests exist."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330. Epub 2018/01/04. 10.3322/caac.21442 .", "ArticleIdList": ["10.3322/caac.21442", "29313949"]}, {"Citation": "Kimiz-Gebologlu I, Gulce-Iz S, Biray-Avci C. Monoclonal antibodies in cancer immunotherapy. Mol Biol Rep. 2018. Epub 2018/10/11. 10.1007/s11033-018-4427-x .", "ArticleIdList": ["10.1007/s11033-018-4427-x", "30311129"]}, {"Citation": "Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, P\u00e9rez-Gracia JL, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2018. Epub 2018/11/09. 10.1038/s41416-018-0328-y .", "ArticleIdList": ["10.1038/s41416-018-0328-y", "PMC6325155", "30413827"]}, {"Citation": "van Willigen WW, Bloemendal M, Gerritsen WR, Schreibelt G, de Vries IJM, Bol KF. Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. Front Immunol. 2018;9:2265 Epub 2018/10/01. 10.3389/fimmu.2018.02265 .", "ArticleIdList": ["10.3389/fimmu.2018.02265", "PMC6174277", "30327656"]}, {"Citation": "Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13(6):370\u201383. Epub 2016/03/22. 10.1038/nrclinonc.2016.36 .", "ArticleIdList": ["10.1038/nrclinonc.2016.36", "PMC5529102", "27000958"]}, {"Citation": "Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6(1):39 Epub 2018/05/16. 10.1186/s40425-018-0349-3 .", "ArticleIdList": ["10.1186/s40425-018-0349-3", "PMC5956851", "29769148"]}, {"Citation": "Kwapisz D. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib. Breast Cancer Res Treat. 2017;166(1):41\u201354. Epub 2017/07/24. 10.1007/s10549-017-4385-3 .", "ArticleIdList": ["10.1007/s10549-017-4385-3", "28741274"]}, {"Citation": "Giordani E, Zoratto F, Strudel M, Papa A, Rossi L, Minozzi M, et al. Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment. Curr Cancer Drug Targets. 2016;16(2):175\u201385. .", "ArticleIdList": ["26278713"]}, {"Citation": "Mayer IA, Arteaga CL. The PI3K/AKT Pathway as a Target for Cancer Treatment. Annu Rev Med. 2016;67:11\u201328. Epub 2015/10/14. 10.1146/annurev-med-062913-051343 .", "ArticleIdList": ["10.1146/annurev-med-062913-051343", "26473415"]}, {"Citation": "Lin Z, Zhang Q, Luo W. Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions. Eur J Pharmacol. 2016;793:76\u201381. Epub 2016/11/11. 10.1016/j.ejphar.2016.10.039 .", "ArticleIdList": ["10.1016/j.ejphar.2016.10.039", "27840192"]}, {"Citation": "Moghadam SE, Ebrahimi SN, Salehi P, Moridi Farimani M, Hamburger M, Jabbarzadeh E. Wound Healing Potential of Chlorogenic Acid and Myricetin-3-O-\u03b2-Rhamnoside Isolated from Parrotia persica. Molecules. 2017;22(9). Epub 2017/09/08. 10.3390/molecules22091501 .", "ArticleIdList": ["10.3390/molecules22091501", "PMC5603238", "28885580"]}, {"Citation": "Hu R, George DJ, Zhang T. What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence. Ther Adv Urol. 2016;8(4):272\u20138. Epub 2016/05/02. 10.1177/1756287216645314 .", "ArticleIdList": ["10.1177/1756287216645314", "PMC5131740", "27928429"]}, {"Citation": "Lin JK, Lerman BJ, Barnes JI, Boursiquot BC, Tan YJ, Robinson AQL, et al. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2018:JCO2018790642. Epub 2018/09/13. 10.1200/JCO.2018.79.0642 .", "ArticleIdList": ["10.1200/JCO.2018.79.0642", "30212291"]}, {"Citation": "Liu D, Zhao J. Cytokine release syndrome: grading, modeling, and new therapy. J Hematol Oncol. 2018;11(1):121 Epub 2018/09/24. 10.1186/s13045-018-0653-x .", "ArticleIdList": ["10.1186/s13045-018-0653-x", "PMC6154787", "30249264"]}, {"Citation": "Cogdill AP, Andrews MC, Wargo JA. Hallmarks of response to immune checkpoint blockade. Br J Cancer. 2017;117(1):1\u20137. Epub 2017/05/18. 10.1038/bjc.2017.136 .", "ArticleIdList": ["10.1038/bjc.2017.136", "PMC5520201", "28524159"]}, {"Citation": "Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, et al. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest. 2011;121(4):1313\u201328. Epub 2011/03/23. 10.1172/JCI42405 .", "ArticleIdList": ["10.1172/JCI42405", "PMC3070607", "21436589"]}, {"Citation": "Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A. 2009;106(16):6742\u20137. Epub 2009/04/03. 10.1073/pnas.0902280106 .", "ArticleIdList": ["10.1073/pnas.0902280106", "PMC2665197", "19346489"]}, {"Citation": "von Tell D, Armulik A, Betsholtz C. Pericytes and vascular stability. Exp Cell Res. 2006;312(5):623\u20139. Epub 2005/11/21. 10.1016/j.yexcr.2005.10.019 .", "ArticleIdList": ["10.1016/j.yexcr.2005.10.019", "16303125"]}, {"Citation": "Semenza GL. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol. 2014;9:47\u201371. Epub 2013/08/07. 10.1146/annurev-pathol-012513-104720 .", "ArticleIdList": ["10.1146/annurev-pathol-012513-104720", "23937437"]}, {"Citation": "Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26(5):605\u201322. Epub 2014/11/10. 10.1016/j.ccell.2014.10.006 .", "ArticleIdList": ["10.1016/j.ccell.2014.10.006", "PMC4269830", "25517747"]}, {"Citation": "Basmadjian C, Zhao Q, Bentouhami E, Djehal A, Nebigil CG, Johnson RA, et al. Cancer wars: natural products strike back. Front Chem. 2014;2:20 Epub 2014/05/01. 10.3389/fchem.2014.00020 .", "ArticleIdList": ["10.3389/fchem.2014.00020", "PMC4013484", "24822174"]}, {"Citation": "Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007;70(3):461\u201377. Epub 2007/02/20. 10.1021/np068054v .", "ArticleIdList": ["10.1021/np068054v", "17309302"]}, {"Citation": "Yanez M, Blanchette J, Jabbarzadeh E. Modulation of Inflammatory Response to Implanted Biomaterials Using Natural Compounds. Curr Pharm Des. 2017;23(41):6347\u201357. Epub 2017/05/20. 10.2174/1381612823666170510124348 .", "ArticleIdList": ["10.2174/1381612823666170510124348", "PMC5681444", "28521709"]}, {"Citation": "Troselj KG, Kujundzic RN. Curcumin in combined cancer therapy. Curr Pharm Des. 2014;20(42):6682\u201396. .", "ArticleIdList": ["25341940"]}, {"Citation": "Wang Y, Yu H, Zhang J, Ge X, Gao J, Zhang Y, et al. Anti-tumor effect of emodin on gynecological cancer cells. Cell Oncol (Dordr). 2015;38(5):353\u201363. Epub 2015/07/11. 10.1007/s13402-015-0234-8 .", "ArticleIdList": ["10.1007/s13402-015-0234-8", "26162964"]}, {"Citation": "Iwanowycz S, Wang J, Hodge J, Wang Y, Yu F, Fan D. Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages. Mol Cancer Ther. 2016;15(8):1931\u201342. Epub 2016/05/18. 10.1158/1535-7163.MCT-15-0987 .", "ArticleIdList": ["10.1158/1535-7163.MCT-15-0987", "PMC4975665", "27196773"]}, {"Citation": "Li L, Hou X, Xu R, Liu C, Tu M. Research review on the pharmacological effects of astragaloside IV. Fundam Clin Pharmacol. 2017;31(1):17\u201336. Epub 2016/09/23. 10.1111/fcp.12232 .", "ArticleIdList": ["10.1111/fcp.12232", "27567103"]}, {"Citation": "Auyeung KK, Mok NL, Wong CM, Cho CH, Ko JK. Astragalus saponins modulate mTOR and ERK signaling to promote apoptosis through the extrinsic pathway in HT-29 colon cancer cells. Int J Mol Med. 2010;26(3):341\u20139. .", "ArticleIdList": ["20664949"]}, {"Citation": "Jiao D, Wang J, Lu W, Tang X, Chen J, Mou H, et al. Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways in lung cancer. Mol Ther Oncolytics. 2016;3:16018 Epub 2016/08/03. 10.1038/mto.2016.18 .", "ArticleIdList": ["10.1038/mto.2016.18", "PMC4972091", "27525306"]}, {"Citation": "Br\u00e5kenhielm E, Cao R, Cao Y. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J. 2001;15(10):1798\u2013800. .", "ArticleIdList": ["11481234"]}, {"Citation": "Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol. 2015;35 Suppl:S224\u2013S43. Epub 2015/01/16. 10.1016/j.semcancer.2015.01.001 .", "ArticleIdList": ["10.1016/j.semcancer.2015.01.001", "PMC4737670", "25600295"]}, {"Citation": "Lu K, Bhat M, Basu S. Plants and their active compounds: natural molecules to target angiogenesis. Angiogenesis. 2016;19(3):287\u201395. Epub 2016/05/06. 10.1007/s10456-016-9512-y .", "ArticleIdList": ["10.1007/s10456-016-9512-y", "PMC4930694", "27154020"]}, {"Citation": "Ai B, Bie Z, Zhang S, Li A. Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment. Am J Cancer Res. 2016;6(8):1624\u201335. Epub 2016/08/01. .", "ArticleIdList": ["PMC5004068", "27648354"]}, {"Citation": "Rutledge KE, Cheng Q, Jabbarzadeh E. Modulation of Inflammatory Response and Induction of Bone Formation Based on Combinatorial Effects of Resveratrol. J Nanomed Nanotechnol. 2016;7(1). Epub 2016/05/14. 10.4172/2157-7439.1000350 .", "ArticleIdList": ["10.4172/2157-7439.1000350", "PMC4862595", "27175310"]}, {"Citation": "Choudhary MI, Hussain A, Adhikari A, Marasini BP, Sattar SA, Wahab At, et al. Anticancer and \u03b1-chymotrypsin inhibting diterpenes and triterpenes from Salvia leriifolia. Phytochemistry Letters. 2013;6:5. Epub December 2012."}, {"Citation": "Farimani MM, Khodaei B, Moradi H, Aliabadi A, Ebrahimi SN, De Mieri M, et al. Phytochemical Study of Salvia leriifolia Roots: Rearranged Abietane Diterpenoids with Antiprotozoal Activity. J Nat Prod. 2018;81(6):1384\u201390. Epub 2018/06/14. 10.1021/acs.jnatprod.7b01019 .", "ArticleIdList": ["10.1021/acs.jnatprod.7b01019", "29896963"]}, {"Citation": "NCI-60 Human Tumor Cell Lines Screen dtp.cancer.gov: National Cancer Institute; 2015 [cited 2018 December 4]. https://dtp.cancer.gov/discovery_development/nci-60/."}, {"Citation": "Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6(10):813\u201323. 10.1038/nrc1951 .", "ArticleIdList": ["10.1038/nrc1951", "16990858"]}, {"Citation": "Berger SH, Barbour KW, Berger FG. A naturally occurring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2'-deoxyuridine in a human colon tumor cell line. Mol Pharmacol. 1988;34(4):480\u20134. .", "ArticleIdList": ["2971872"]}, {"Citation": "Bunel V, Ouedraogo M, Nguyen AT, St\u00e9vigny C, Duez P. Methods applied to the in vitro primary toxicology testing of natural products: state of the art, strengths, and limits. Planta Med. 2014;80(14):1210\u201326. Epub 2014/01/15. 10.1055/s-0033-1360273 .", "ArticleIdList": ["10.1055/s-0033-1360273", "24431017"]}, {"Citation": "Taylor WF, Jabbarzadeh E. The use of natural products to target cancer stem cells. Am J Cancer Res. 2017;7(7):1588\u2013605. Epub 2017/07/01. .", "ArticleIdList": ["PMC5523038", "28744407"]}, {"Citation": "Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol. 2004;16(6):663\u20139. 10.1016/j.ceb.2004.09.011 .", "ArticleIdList": ["10.1016/j.ceb.2004.09.011", "15530778"]}, {"Citation": "Chen T, Stephens PA, Middleton FK, Curtin NJ. Targeting the S and G2 checkpoint to treat cancer. Drug Discov Today. 2012;17(5\u20136):194\u2013202. Epub 2011/12/15. 10.1016/j.drudis.2011.12.009 .", "ArticleIdList": ["10.1016/j.drudis.2011.12.009", "22192883"]}, {"Citation": "Chaffer CL, San Juan BP, Lim E, Weinberg RA. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016;35(4):645\u201354. 10.1007/s10555-016-9648-7 .", "ArticleIdList": ["10.1007/s10555-016-9648-7", "27878502"]}]}], "History": [{"Year": "2019", "Month": "3", "Day": "22"}, {"Year": "2019", "Month": "5", "Day": "27"}, {"Year": "2019", "Month": "6", "Day": "12", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "6", "Day": "12", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "2", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "6", "Day": "11"}], "PublicationStatus": "epublish", "ArticleIdList": ["31185048", "PMC6559640", "10.1371/journal.pone.0218125", "PONE-D-19-08281"]}}]}